CCL1 Protein (AA 24-92)

Catalog No. ABIN2666951

Product Details

Target: CCL1 (Chemokine (C-C Motif) Ligand 1 (CCL1))

Protein Type: Recombinant

Biological Activity: Active

Protein Characteristics: AA 24-92

Origin: Mouse

Source: HEK-293 Cells

Application: Western Blotting (WB)

Purity: > 98 % , as determined by Coomassie stained SDS-PAGE.

Sterility: 0.22 μm filtered

Endotoxin Level:

Less than 0.01 ng per μg cytokine as determined by the LAL method.

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

Biological activity: Bioactivity was measured by its property to chemoattract mouse BW.5147.G.1.4OUAR.1 cells in a dose dependent manner.

Restrictions: For Research Use only

Handling

Format: Liquid

Reconstitution: For maximum results, quick spin vial prior to opening. Stock solutions should be prepared at no less than 10 μg/mL in sterile buffer (PBS, HPBS, DPBS, and EBSS) containing carrier protein such as 1 % BSA, or HAS. After dilution, the cytokine can be stored between 2 °C and 8 °C for one month or from -20 °C to -70 °C for up to 3 months.

Buffer: 0.22 μm filtered protein solution is in PBS.

Handling Advice: Avoid repeated freeze/thaw cycles.

Storage: -20 °C

Storage Comment: Unopened vial can be stored between 2°C and 8°C for three months, at -20°C for six months, or at -70°C for one year.

Target Details

Target: CCL1 (Chemokine (C-C Motif) Ligand 1 (CCL1))

Alternative Name: CCL1 (CCL1 Products)

Synonyms: I-309 Protein, P500 Protein, SCYA1 Protein, SISe Protein, TCA3 Protein, BF534335 Protein, Scya1 Protein, Tca-3 Protein, CCLi6 Protein, chemokine Protein, C-C motif chemokine ligand 1 Protein, chemokine (C-C motif) ligand 1 Protein, CCL1 Protein, Ccl1 Protein

Background: CCL1 was initially identified as a secreted protein derived from activated T cells. CCL1/CCR8 axis is involved in the recruitment of Th2 effector cells in vivo to sites of allergic mucosal inflammation, as a result, there is an increase of CCR8+ CD4 T cell numbers in allergic asthma and a higher concentration of CCL1 in bronchoalveolar lavage of asthmatics patients compared with normal controls. In addition, high levels of CCL1 have been detected in serum of patients with atopic dermatitis. Also, CCL1 is constitutively expressed in normal skin, and CD8 and CD4 CCR8+ cells have been isolated from normal skin. Therefore, it has been suggested that CCL1/CCR8 play a role in skin immunosurveillance. In addition, a more recent publication showed that CCL1 transcript is upregulated in CD4 converted to Tregs by TGF-β in vitro, and this transcriptional upregulation is reversed by IL-6. This data suggests that CCL1 plays a role in Treg conversion. Also, antibodies against CCL1 inhibit the suppressive function of Tregs. Furthermore, the antitumor effect of CpG-ODN plus anti-CCL1 in BALB-neuT mice suggest that neutralization of CCL1 can be used as an adjuvant to antitumor immunotherapy.

Molecular Weight: The 69 amino acid recombinant protein has a predicted molecular mass of approximately 7.7 kDa. The DTT-reduced protein migrates at approximately 16 kDa and non-reduced protein migrates at approximately 18-20 kDa by SDS-PAGE. The N-terminal amino acid is L